Who is sponsoring NCT03942354?

NCT03942354 is sponsored by Medecins Sans Frontieres, Netherlands.

What drugs are being tested in NCT03942354?

Interventions in NCT03942354: Bedaquiline, Pretomanid, Moxifloxacin, Linezolid, Clofazimine, Directly observed therapy (DOT).

What condition does NCT03942354 study?

NCT03942354 studies Multidrug Resistant Tuberculosis.

Is NCT03942354 still recruiting?

NCT03942354 is currently completed. Last updated 29 May 2024.

Last reviewed 2024-05-29 · How we verify

NCT03942354: PRACTECAL-PRO

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Patient-reported Experiences and Quality of Life Outcomes in the TB-PRACTECAL Clinical Trial

Completed Last updated 29 May 2024

What this trial tests

trial testing Bedaquiline in Multidrug Resistant Tuberculosis in 137 participants. Completed in 10 May 2022.

Timeline

1 September 2019

Primary endpoint
10 May 2022

10 May 2022

Quick facts

Lead sponsor	Medecins Sans Frontieres, Netherlands
Status	Completed
Study type	OBSERVATIONAL
Enrollment	137
Start date	1 September 2019
Primary completion	10 May 2022
Estimated completion	10 May 2022
Sites	6 locations across South Africa, Uzbekistan, Belarus

Drugs / interventions tested

Bedaquiline (bedaquiline) — full drug profile →
Pretomanid
Moxifloxacin (moxifloxacin) — full drug profile →
Linezolid — full drug profile →
Clofazimine (clofazimine) — full drug profile →
Directly observed therapy (DOT)

Conditions studied

Multidrug Resistant Tuberculosis — all drugs for Multidrug Resistant Tuberculosis →

Sponsor

Medecins Sans Frontieres, Netherlands — full company profile →

Who can join

18 and older, any sex, with Multidrug Resistant Tuberculosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

PRACTECAL-PRO is a sub-study of a TB-PRACTECAL clinical trial for multidrug resistant Tuberculosis. It evaluates the effectiveness of TB-PRACTECAL interventions from the patient perspective in terms of their quality of life, shared decision making and satisfaction with services.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Capturing patient-reported and quality of life outcomes with use of shorter regimens for drug-resistant tuberculosis: mixed-methods substudy protocol, TB PRACTECAL-PRO.
Stringer B, Lowton K, James N, Nyang'wa BT. · · 2021 · cited 8× · PMID 34489263 · DOI 10.1136/bmjopen-2020-043954
Quality of life outcomes and patient-reported experiences in a randomised controlled trial for rifampicin-resistant TB (PRACTECAL-PRO): a mixed-methods study.
Lowton K, Stringer B, Cusinato M, Fielding K, et al · · 2026 · PMID 42125015 · DOI 10.5588/ijtldopen.25.0823

Verify or expand the search:

Other trials of Bedaquiline

Trials testing the same drug.

NCT06192160 — Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis · Phase 2 · recruiting
NCT06081361 — Innovating Shorter, All- Oral, Precised, Individualized Treatment Regimen for Rifampicin Resistant Tuberculosis：Contezol · Phase 3 · active not recruiting
NCT05766267 — Short-course Regimens for the Treatment of Pulmonary Tuberculosis · Phase 2, PHASE3 · active not recruiting
NCT05824871 — A Phase III Study of Oral Sudapyridine (WX-081) Tablets in Rifampicin-Resistant Pulmonary Tuberculosis Patients · Phase 3 · recruiting
NCT05382312 — Early Bactericidal Activity, Safety & Tolerability of Oral GSK3036656 in a Dual Combination With Novel and Established A · Phase 2 · completed

Other recruiting trials for Multidrug Resistant Tuberculosis

Currently open trials in the same condition.

NCT05081401 — Innovating(IN) Shorter(S), All- Oral, Precised(P), Individualized(I) Treatment Regimen(RE) for Rifampicin Resistant Tube · Phase 3 · recruiting

Other Medecins Sans Frontieres, Netherlands trials

Trials by the same sponsor.

NCT04268524 — Randomised Clinical Trial for New Treatment Modalities for Cutaneous Leishmaniasis Caused by Leishmania Tropica, in Paki · Phase 3 · recruiting
NCT04207112 — Economic Evaluation of New MDR TB Regimens · Phase 2, PHASE3 · completed
NCT04081077 — PRACTECAL-PKPD Sub Study · Phase 2, PHASE3 · unknown
NCT03208543 — Effectiveness, Safety and Feasibility of HECT-CL, in Quetta, Pakistan · Phase 3 · terminated
NCT03311607 — Safety and Effectiveness of Short-course AmBisome in the Treatment of PKDL in Bangladesh · Phase 4 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03942354 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Medecins Sans Frontieres, Netherlands
Last refreshed: 29 May 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03942354.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing